Letrozole Sandoz

Letrozole, the active ingredient in Letrozole Sandoz, is an aromatase inhibitor presented as an oral tablet for oral use. Approved in the European Union, it lowers estrogen synthesis and is employed to treat hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company provides the product under strict quality standards to meet global oncology treatment needs.

Letrozole is used in the management of estrogen‑dependent breast cancer, acting on postmenopausal disease pathways.

- Metastatic breast cancer: slows disease progression in postmenopausal women with hormone‑receptor positive tumors. - Adjuvant therapy for early‑stage breast cancer: reduces risk of recurrence after surgery in postmenopausal patients. - Neoadjuvant treatment: shrinks tumor size before surgery in eligible postmenopausal women.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Elevated cholesterol levels

Serious or Rare Side Effects: - Severe bone loss or osteoporosis - Significant liver enzyme elevation - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Cardiovascular complications (myocardial infarction, stroke) - Severe allergic reactions (anaphylaxis, skin rash) - Interstitial lung disease or pneumonitis

Before initiating Letrozole, consider the following precautions to ensure safe use.

- Pregnancy: contraindicated in pregnancy; drug is teratogenic (Category X). - Breastfeeding: not recommended; may be excreted in breast milk. - Bone health: monitor bone mineral density; consider calcium and vitamin D supplementation. - Cardiovascular risk: assess baseline cardiovascular status, especially in patients with hypertension or hyperlipidemia. - Liver function: evaluate hepatic function; dose adjustment may be needed in severe impairment. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Letrozole can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce Letrozole exposure. - Strong CYP2C19 inhibitors (e.g., fluconazole) may increase Letrozole levels. - Estrogen replacement therapy antagonizes Letrozole's effect. - Tamoxifen may diminish Letrozole efficacy when used concurrently. - Warfarin may have increased anticoagulant effect.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine) may affect Letrozole metabolism. - Statins (e.g., simvastatin) may increase risk of myopathy. - Bisphosphonates used for bone health may require monitoring. - NSAIDs may increase risk of gastrointestinal upset. - Thyroid hormone replacement may need dose adjustment.